Herpes Doctor

Genital Herpes Forum

Herpes News Archive

Archived information and news relating the the Herpes family of viruses, treatments and studies.

Herpes Simplex to Battle Brain Tumors

Posted Tue, 08/03/2004 - 08:48 by jack

The BBC are reporting that Glasgow University have been granted approval for a large scale clinical trial using a modified Herpes Simplex virus to battle glioma (an aggressive type of brain tumor).

ViroPharma Initiates Maribavir Phase 2 Program In Bone Marrow Transplant Patients

Posted Tue, 07/27/2004 - 08:45 by jack

EXTON, Pa., July 27, 2004 -- ViroPharma Incorporated (Nasdaq:VPHM) today announced the initiation of its Phase 2 clinical program for maribavir, an oral antiviral drug that inhibits cytomegalovirus (CMV), in allogeneic bone marrow (stem cell) transplant patients. Preliminary data from the Phase 1 maribavir program presented recently at the Company's pre-Phase 2 clinical investigator's meeting showed a favorable safety and pharmacokinetic profile for maribavir.

Valacyclovir More Effective than Acyclovir Against Herpes Zoster

Posted Tue, 07/20/2004 - 10:34 by jack

In a new article about the treatment of Post Herpetic Neuralgia at The Journal Pharmacy Technology the conclusion is drawn that Valacyclovir is far more effective than Acyclovir in the treatment of Post Herpetic Neuralgia

HIV/AIDS - Suppresive Therapy for HSV2 Still Needed

Posted Tue, 07/20/2004 - 08:59 by jack

As the struggle to find an answer to the problem surrounding HIV/AIDS patients and the complications that HSV2 - Genital Herpes and CMV can cause continues. Aidsmap.com report on the discovery that HAART (combination therapy) treated HIV/AIDS patients saw no significant reduction in the shedding of the HSV2 virus.

You can catch the full story here.

ViroPharma Announces 'Teach-In' on Cytomegalovirus Infection

Posted Tue, 07/20/2004 - 08:05 by jack

EXTON, Pa., July 16, 2004 -- ViroPharma Incorporated (Nasdaq:VPHM) announced today that the company will host a 'Teach-in' on cytomegalovirus (CMV) infection at the Plaza Hotel in New York City at 5:00 P.M. Eastern Time on July 21, 2004. At the meeting, transplant physicians and members of senior management will provide an overview of CMV in the immunocompromised and transplant setting, the challenges of managing patients at risk of CMV infection, currently available treatments, the opportunities for new therapies, and an overview of maribavir, ViroPharma's leading clinical candidate molecule that inhibits CMV.